MeiraGTx Holdings (MGTX) Return on Capital Employed (2018 - 2025)
MeiraGTx Holdings' (MGTX) quarterly Return on Capital Employed came in at 49.19% in Q4 2025, up 939.0% YoY from 4.73% in Q4 2024, and up 87.04% on a QoQ basis from 379.67% in Q3 2025.
MeiraGTx Holdings (MGTX) Return on Capital Employed (2018 - 2025) Analysis & Trends
MeiraGTx Holdings (MGTX) has 8 years of Return on Capital Employed data on file, last reported at 49.19% in Q4 2025.
- Quarterly Return on Capital Employed rose 939.0% year-over-year to 49.19% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 49.19% (up 939.0% YoY) and the FY2025 annual result came in at 44.47%, up 1076.0% from the prior year.
- Return on Capital Employed grew to 49.19% in Q4 2025, from 379.67% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 180.22% in Q2 2023 to a low of 379.67% in Q3 2025.
- A 5-year average of 32.3% and a median of 52.71% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed soared 13242 bps — and 2025, when it plunged 32358 bps.
- Tracing MGTX's Return on Capital Employed over 5 years: stood at 77.43% in 2021, then slumped by 86 bps to 143.92% in 2022, then jumped by 75 bps to 36.55% in 2023, then sank by 60 bps to 58.58% in 2024, then increased by 16 bps to 49.19% in 2025.
- The last three Return on Capital Employed figures came in at 49.19% (Q4 2025), 379.67% (Q3 2025), and 94.72% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | MeiraGTx Holdings | 1.10 Bn | 1.03 Bn | - | -49.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -49.19% |
| Sep 30, 2025 | -379.67% |
| Jun 30, 2025 | -94.72% |
| Mar 31, 2025 | -81.96% |
| Dec 31, 2024 | -58.58% |
| Sep 30, 2024 | -56.09% |
| Jun 30, 2024 | -49.34% |
| Mar 31, 2024 | -36.62% |
| Dec 31, 2023 | -36.55% |
| Sep 30, 2023 | -188.51% |
| Jun 30, 2023 | 180.22% |
| Mar 31, 2023 | -149.98% |
| Dec 31, 2022 | -143.92% |
| Sep 30, 2022 | 128.03% |
| Jun 30, 2022 | 139.10% |
| Mar 31, 2022 | -80.37% |
| Dec 31, 2021 | -77.43% |
| Sep 30, 2021 | 139.73% |
| Jun 30, 2021 | 117.07% |
| Mar 31, 2021 | 132.87% |